Date closed: 9/26/2016

Value: C$21 million

On September 26, 2016, The Fonds de solidarité FTQ, CTI Life Sciences Fund and Servier Canada announced the creation of ILKOS THERAPEUTICS Inc., a new Québec biotechnology firm tasked with the development of S42909, a compound indicated in the treatment of venous lower limb ulcers.

BLG represented Servier Canada with a team led by André Dufour that included Pascal de Guise, Yaniv Saragosti and Calvin Leung.